Abstract
This work aims at comparing alterations in the proteomes of human epithelial ovarian cancer xenografts between stressed and non-stressed immunodeficient mice as well as exploring the molecular mechanisms linking chronic psychological stress to ovarian cancer oncogenesis and progression. SK-OV-3 cells were injected subcutaneously into nude mice. The stress group was subjected to a chronic physical restraint protocol for 6 h on 35 consecutive days, while the control group was unrestrained. All mice were sacrificed on day 36 after SK-OV-3 cell injection, and tumors were excised. Tumor tissues were processed for 2D gel electrophoresis, mass spectrometry (nanoUPLC-ESI-MS/MS) and Western blotting. The expression of 20 proteins was found to be significantly altered between the stress and control groups, of which 14 were up-regulated, five were down-regulated, and one protein was found only in the stress group. All proteins were identified by UPLC-ESI-MS/MS, and Western blotting results were consistent with those of proteomic methods. The present results provide new evidence relating to the molecular mechanism underlying the relationship between psychological stress and tumor progression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lynch H T, Casey M J, Lynch J, et al. Genetics and ovarian carcinoma. Semin Oncol, 1998, 25: 265–280, 1:STN:280:DyaK1c3psFGqtQ%3D%3D, 9633840
Li Z, Zhao X, Yang J, et al. Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain. Sci China Ser C-Life Sci, 2005, 48: 648–657, 1:CAS:528:DC%2BD28Xhs1Khs7k%3D, 10.1360/062004-84
Kiecolt-Glaser J K, Robles T F, Heffner K L, et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol, 2002, 13: 165–169, 12401684
Antoni M H. Psychoneuroendocrinology and psychoneuroimmunology of cancer: plausible mechanisms worth pursuing. Brain Behav Immun, 2003, 17: 84–91, 10.1016/S0889-1591(02)00074-0
Boyce E A, Kohn E C. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer, 2005, 15: 266–273, 16343243, 10.1111/j.1525-1438.2005.00434.x
Philip R, Murthy S, Krakover J, et al. Shared Immuno-proteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res, 2007, 6: 2509–2517, 1:CAS:528:DC%2BD2sXmtVKksbc%3D, 17547437, 10.1021/pr0606777
Gortzak-Uzan L, Ignatchenko A, Evangelou A I, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res, 2008, 7: 339–351, 1:CAS:528:DC%2BD2sXhsVamsbvI, 18076136, 10.1021/pr0703223
Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tis sues by proteomic patterns. Proteomics, 2006, 6: 5846–5856, 1:CAS:528:DC%2BD28Xht1yqsbbP, 17068758, 10.1002/pmic.200600165
Wang J, Zhang X, Ge X, et al. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol, 2008, 111: 111–119, 1:CAS:528:DC%2BD1cXhtFOgsr7E, 18703221, 10.1016/j.ygyno.2008.06.031
Young T, Mei F, Liu J, et al. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24: 6174–6184, 1:CAS:528:DC%2BD2MXpvFertL8%3D, 15940260, 10.1038/sj.onc.1208753
Jackson D, Craven R A, Hutson R C, et al. Proteomic profiling identifies afamin as a potential biomarkerfor ovarian cancer. Clin Cancer Res, 2007, 13: 7370–7379, 1:CAS:528:DC%2BD2sXhsVCktrzF, 18094419, 10.1158/1078-0432.CCR-07-0747
Davidson B, Espina V, Steinberg S M, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res, 2006, 12: 791–799, 1:CAS:528:DC%2BD28XhtFeiur8%3D, 16467090, 10.1158/1078-0432.CCR-05-2516
Ye B, Cramer D W, Skates S J, et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res, 2003, 9: 2904–2911, 1:CAS:528:DC%2BD3sXmtF2iu70%3D, 12912935
Uys J D, Hattingh S M, Stein D J, et al. Large scale hippocampal cellular distress may explain the behavioral consequences of repetitive traumatic experiences—a proteomic approach. Neurochem Res, 2008, 33: 1724–1734, 1:CAS:528:DC%2BD1cXptVKgt7o%3D, 18307038, 10.1007/s11064-008-9615-y
Teague C R, Dhabhar F S, Barton R H, et al. Metabonomic studies on the physiological effects of acute and chronic psychological stress in Sprague-Dawley rats. J Proteome Res, 2007, 6: 2080–2093, 1:CAS:528:DC%2BD2sXkvValtbc%3D, 17474765, 10.1021/pr060412s
Carboni L, Piubelli C, Pozzato C, et al. Proteomic analysis of rat hippocampus after repeated psychological stress. Neuroscience, 2006, 137: 1237–1246, 1:CAS:528:DC%2BD28Xos1elsQ%3D%3D, 16338082, 10.1016/j.neuroscience.2005.10.045
Masters J R, Thomson J A, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for cell lines. Proc Natl Acad Sci USA, 2001, 98: 8012–8017, 1:CAS:528:DC%2BD3MXlt1Kntbo%3D, 11416159, 10.1073/pnas.121616198
Park S J, Kim M J, Kim H B, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol, 2009, 77: 1328–1336, 1:CAS:528:DC%2BD1MXjsFSgsr4%3D, 19426671, 10.1016/j.bcp.2008.12.027
Stangelberger A, Schally A V, Varga J L, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res, 2005, 11: 49–57, 1:CAS:528:DC%2BD2MXhtVehtbY%3D, 15671527
Alfonso J, Frick L R, Silberman D M, et al. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biol Psychiatry, 2006, 59: 244–251, 1:CAS:528:DC%2BD28Xhtlaqu7s%3D, 16140276, 10.1016/j.biopsych.2005.06.036
Sheridan J F, Dobbs C, Jung J, et al. Stress-induced neuroendocrine modulation of viral pathogenesis and immunity. Ann NY Acad Sci, 1998, 840: 803–808, 1:CAS:528:DyaK1cXktFSgsbs%3D, 9629306, 10.1111/j.1749-6632.1998.tb09618.x
Kim S, Park Y W, Schiff B A, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11: 1713–1721, 1:CAS:528:DC%2BD2MXitVKrsrw%3D, 15755992, 10.1158/1078-0432.CCR-04-1908
Winter D, Kugelstadt D, Seidler J, et al. Protein phosphorylation influences proteolytic cleavage and kinase substrate properties exemplified by analysis of in vitro phosphorylated Plasmodium falciparum glideosome-associated protein 45 by nano-ultra performance liquidchromatographytandem mass spectrometry. Anal Biochem, 2009, 393: 41–47, 1:CAS:528:DC%2BD1MXptVertrc%3D, 19549500, 10.1016/j.ab.2009.06.022
Culp W D, Neal R, Massey R, et al. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res, 2006, 5: 1332–1343, 1:CAS:528:DC%2BD28Xkt12msrY%3D, 16739985, 10.1021/pr060059q
Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 2003, 1: 682–689, 1:CAS:528:DC%2BD3sXltl2ku7k%3D, 12861054
Kim J H, Bogner P N, Baek S H, et al. Up-regulation of peroxiredoxin1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res, 2008, 14: 2326–2333, 1:CAS:528:DC%2BD1cXkvFGmtLs%3D, 18413821, 10.1158/1078-0432.CCR-07-4457
Kang D, Lee K M, Park S K, et al. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev, 2007, 16: 1581–1586, 1:CAS:528:DC%2BD2sXos1equ7w%3D, 17646272, 10.1158/1055-9965.EPI-06-0895
Hirose K, Longo D L, Oppenheim J J, et al. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J, 1993, 7: 361–368, 1:CAS:528:DyaK3sXhs1Kgt7s%3D, 8440412
Brown D P, Chin-Sinex H, Nie B, et al. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol, 2009, 63: 723–730, 1:CAS:528:DC%2BD1MXhtVegsLw%3D, 18622615, 10.1007/s00280-008-0791-x
Durany N, Joseph J, Jimenez O M, et al. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer, 2000, 82: 20–27, 1:CAS:528:DC%2BD3cXltFWmug%3D%3D, 10638961, 10.1054/bjoc.1999.0871
Hwang T L, Liang Y, Chien K Y, et al. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics, 2006, 6: 2259–2272, 1:CAS:528:DC%2BD28Xjslyrtrw%3D, 16493704, 10.1002/pmic.200500345
Tang S J, Ho M Y, Cho H C, et al. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer, 2008, 123: 2840–2848, 1:CAS:528:DC%2BD1cXhsVKgtrfF, 18814280, 10.1002/ijc.23888
Pogue-Geile K, Geiser J R, Shu M, et al. Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol, 1991, 11: 3842–3849, 1:CAS:528:DyaK38Xhs1Onu7Y%3D, 1712897
Marty L, Taviaux S, Fort P. Expression and human chromosomal localization to 17q25 of the growth-regulated gene encoding the mitochondrial ribosomal protein MRPL12. Genomics, 1997, 41: 453–457, 1:CAS:528:DyaK2sXivF2ru7Y%3D, 9169145, 10.1006/geno.1997.4691
Youn B S, Kim D S, Kim J W, et al. NM23 as a prognostic biomarker in ovarian serous carcinoma. Mod Pathol, 2008, 21: 885–892, 1:CAS:528:DC%2BD1cXnsFOgsrY%3D, 18408655, 10.1038/modpathol.2008.64
Schneider J, Pollán M, Jiménez E, et al. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer, 2000, 82: 1662–1670, 1:CAS:528:DC%2BD3cXjvVCgsrc%3D, 10817501, 10.1054/bjoc.2000.1116
Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics, 2004, 4: 3246–3267, 1:CAS:528:DC%2BD2cXovVyntLo%3D, 15378690, 10.1002/pmic.200400835
Satoh K, Narumi K, Abe T, et al. Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells. Br J Cancer, 1999, 80: 1115–1122, 1:CAS:528:DyaK1MXkt1ClsLo%3D, 10376960, 10.1038/sj.bjc.6690474
Young L J, Lee E Y, To H A, et al. Human esterase D gene: complete cDNA sequence, genomic structure and application in the genetic diagnosis of human retinoblastoma. Hum Genet, 1988, 79: 137–141, 1:CAS:528:DyaL1MXhs1OjurY%3D, 3164702, 10.1007/BF00280552
Xia C, Meng Q, Liu L Z, et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res, 2007, 67: 10823–10830, 1:CAS:528:DC%2BD2sXhtlSls7fF, 18006827, 10.1158/0008-5472.CAN-07-0783
Zhou X, Liu Y, You J, et al. Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett, 2008, 270: 312–327, 1:CAS:528:DC%2BD1cXhtFekt7%2FN, 18710790, 10.1016/j.canlet.2008.05.028
Ren K, Jin H, Bian C, et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem, 2008, 283: 35598–35605, 1:CAS:528:DC%2BD1cXhsVylsrvE, 18948272, 10.1074/jbc.M802253200
Myung J K, Afjehi-Sadat L, Felizardo-Cabatic M, et al. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci, 2004, 2: 8–13, 15598346, 10.1186/1477-5956-2-8
Ando T, Ishiguro H, Kimura M, et al. Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Dis Esophagus, 2006, 19: 454–458, 1:STN:280:DC%2BD28njsVWqsw%3D%3D, 17069588, 10.1111/j.1442-2050.2006.00618.x
Ellen T P, Ke Q, Zhang P, et al. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis, 2008, 29: 2–8, 1:CAS:528:DC%2BD1cXhs1aitr0%3D, 17916902, 10.1093/carcin/bgm200
Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8: 355–368, 1:CAS:528:DC%2BD2MXht12gsbvJ, 16286244, 10.1016/j.ccr.2005.10.015
Ouellet V, Le Page C, Guyot M C, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer, 2006, 119: 2119–2126, 1:CAS:528:DC%2BD28XhtVSksL7N, 16823850, 10.1002/ijc.22054
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Gao, J., Gao, G., Zhang, Y. et al. Proteomic analysis of human epithelial ovarian cancer xenografts in immunodeficient mice exposed to chronic psychological stress. Sci. China Life Sci. 54, 112–120 (2011). https://doi.org/10.1007/s11427-010-4126-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-010-4126-x